Where next for gefitinib in patients with lung cancer? (Q36496065)

14 August 2017

title

Where next for gefitinib in patients with lung cancer? (English)

1 reference

14 August 2017

Fiona Blackhall

1

1 reference

14 August 2017

Malcolm Ranson

series ordinal

2

1 reference

14 August 2017

Nick Thatcher

series ordinal

3

1 reference

14 August 2017

publication date

1 June 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

499-507

1 reference

publication type of scholarly work

14 August 2017

review article

1 reference

Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer : a realistic goal?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

The EGF receptor family as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970725-2

7 January 2021

10.1016/S1470-2045(06)70725-2

Identifiers

DOI

1 reference

14 August 2017

1 reference